Molecular Therapy

Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy''s 2015 impact factor is 6.938.

Molecular Therapy — Methods & Clinical Developments

The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella.

Topics of particular interest within the journal''s scope include:

• Gene vector engineering and production
• Methods for targeted genome editing and engineering
• Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells
• Methods for gene and cell vector delivery
• Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine
• Analysis of gene and cell vector biodistribution and tracking
• Pharmacology/toxicology studies of new and next-generation vectors
• Methods for cell isolation, engineering, culture, expansion, and transplantation
• Cell processing, storage, and banking for therapeutic application
• Preclinical and QC/QA assay development
• Translational and clinical scale-up and Good Manufacturing procedures and process development
• Clinical protocol development
• Computational and bioinformatic methods for analysis, modeling, or visualization of biological data
• Negotiating the regulatory approval process and obtaining such approval for clinical trials